% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • llabtechtwo llabtechtwo May 7, 2013 10:11 PM Flag


    Another sweet beat! Loving this company!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yes, they know how to present the results in the most favorable light...And, not arguing,- the results are great, but at this point it is very hard to evaluate ONXX. Also, no world about using/trying Kypro as first line. All in all it was great (as usual lately) CC and we, probably, will see jump to $93-$94 tomorrow. The bigger question is will it signal the reverse of the trend? I wish it was,but not sure at all...

      • 1 Reply to kot882001
      • The CC talked a lot about Oprozomib, an oral proteosome inhibitor, which should be the follow up to Kyprolis. Looks like they have selected a formulation to move forward in phase II trials. As far as Kyprolis, sale numbers were excellent, and at almost $60 million in Q1 so we shouldn't be surprised to see sales are well over $300 million this year. Foreign sales aren't even part of this number. ONXX did talk about some penetration into 2nd line (low single digits percentage), but that isn't something they can push because it isn't part of the FDA approved label.